Victoria Tomlin, NP
Nurse Practitioner · Raphine, VANPI 1639618416
Payments from drug & device makers
Across 193 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$889
- Lilly USA, LLC$458
- Pfizer$390
- Novo Nordisk$310
- Merck$183
- Amarin Pharma, Inc.$148
- plus $930 from 19 others
What the payments were for
- Food & beverage$3,308100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $889 |
| Lilly USA, LLC | 29 | $458 |
| Pfizer | 36 | $390 |
| Novo Nordisk | 15 | $310 |
| Merck | 10 | $183 |
| Amarin Pharma, Inc. | 10 | $148 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $140 |
| AstraZeneca | 7 | $101 |
| Biohaven Pharmaceuticals, Inc. | 3 | $100 |
| Novartis | 6 | $93 |
| Amgen | 6 | $87 |
| Exact Sciences | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Abbott | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Merz North America, Inc. | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| GSK | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,308 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $79,304 |
| EliquisApixaban | 40 | $46,795 |
| JardianceEmpagliflozin | 51 | $46,058 |
| OzempicSemaglutide | 43 | $41,278 |
| Nurtec OdtRimegepant Sulfate | 12 | $23,969 |
| FarxigaDapagliflozin Propanediol | 23 | $18,431 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,507 |
| LinzessLinaclotide | 11 | $5,962 |
| LevemirInsulin Detemir | 13 | $2,608 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 11 | $2,434 |
| Celecoxib | 30 | $2,244 |
| Valsartan | 79 | $2,195 |
| Rosuvastatin Calcium | 165 | $1,889 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,790 |
| Omeprazole | 184 | $1,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $458 | $79,30469 claims |
| PfizerEliquis, Nurtec Odt | $390 | $70,76452 claims |
| Boehringer IngelheimJardiance | $14 | $46,05851 claims |
| Novo NordiskOzempic, Levemir | $310 | $43,88656 claims |
| AstraZenecaFarxiga | $101 | $18,43123 claims |
| GSKTrelegy Ellipta, Shingrix | $17 | $9,94123 claims |
| AbbVieLinzess, Synthroid | $889 | $6,54723 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $60 | $2,19579 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $88088 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Raphine
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Rachel AndersonCharlottesville$90K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
- Sasha LeeVirginia Beach$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.